Table 3

Incidence of grade 3/4 adverse events in a randomized study of rituximab plus CHOP versus CHOP alone in elderly patients with diffuse, large B cell lymphoma

Regimen


Adverse event

CHOP

Rituximab + CHOP


Any grade 3/4 adverse event (including grade 2 infections)

145 (74.0)

159 (78.7)

Infections

Bronchitis

16 (8.2)

22 (10.9)

Urinary tract infection

17 (8.7)

19 (9.4)

Pneumonia

13 (6.6)

10 (5.0)

Febrile neutropenia

47 (24.0)

45 (22.3)

Respiratory disorders

Dyspnoea

6 (3.1)

16 (7.9)

Cough

6 (3.1)

8 (4.0)

Rhinitis

5 (2.6)

1 (0.5)

General disorders and administration site disorders

Pyrexia

32 (16.3)

26 (12.9)

Fatigue

13 (6.6)

8 (4.0)

General physical health deterioration

10 (5.1)

10 (5.0)

Gastrointestinal disorders

Vomiting

12 (6.1)

8 (4.0)

Abdominal pain

7 (3.6)

12 (5.9)


Values are expressed as n (%). CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone. Data from [30].

Hainsworth Arthritis Res Ther 2003 5(Suppl 4):S12-S16   doi:10.1186/ar1008